Friday, July 10, 2026

pharma · Pulmonary Hypertension Associated with Interstitial Lung Disease · Pulmonary Arterial Hypertension

Insmed Incorporated

Insmed is a pharma organization headquartered in GB. Primary therapeutic focus areas include Pulmonary Hypertension Associated with Interstitial Lung Disease, Pulmonary Arterial Hypertension, Chronic Rhinosinusitis witho

Bridgewater Township, USA HQ
1,666 Employees
EMA registrant Type
Company details
Status
Public
HQ
Bridgewater Township, USA
Employees
1,666
Programs
7
Drugs
18
Patents
0
Clinical program

INS-416

Phase 3 · small molecule · "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"

INS-416 for "Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)" is a Phase 3 program (small_molecule) at Insmed Limited with 1 ClinicalTrials.gov record(s).

← All Insmed Limited projects Phase 3 small molecule active

Internal code INS-416

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Insmed Limited
Phase
Phase 3
Modality
small_molecule
Indication
"Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)"
Status
active
Trials
1